Cemiplimab in the treatment of non-small cell lung cancer
Authors:
L. Koubková
Authors‘ workplace:
Pneumologická klinika 2. LF UK a FN Motol, Praha
Published in:
Klin Onkol 2025; 38(2): 90-96
Category:
Reviews
doi:
https://doi.org/10.48095/ccko202590
Overview
Background: Immuno-oncotherapy is already the standard treatment for non-small cell lung cancer (NSCLC), not only for metastatic disease, but also for locally advanced disease as well as early, operable stages. Aim: The article provides an overview of the updated results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 studies. The studies evaluated the efficacy of cemiplimab (a monoclonal antibody that binds to the programmed cell death receptor – PD-1) in patients with metastatic and locally advanced NSCLC who are not surgery and chemoradiation candidates. We also present the experience from our institution, when cemiplimab was administered as monotherapy in patients with high PD-L1 ligand expression. Conclusion: Cemiplimab demonstrated efficacy as monotherapy in patients with NSCLC expressing PD-L1 in ≥ 50% of tumor cells and in combination with platinum-doublet chemotherapy when expressing PD-L1 in ≥ 1% of tumor cells in the first-line treatment of metastatic but also unresectable locally advanced disease unsuitable for definitive chemoradiation, demonstrating a new treatment option for these patients.
Keywords:
immunotherapy – PD-L1 – PD-1 – advanced non-small cell lung cancer – cemiplimab
Sources
1. World Health Organization. Global cancer burden growing, amidst mounting need for services. Available from: https: //www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for- services.
2. EMA. LIBTAYO (cemiplimab), souhrn údajů o pří- pravku. Dostupné z: https: //ec.europa.eu/health/ documents/community-register/2020/202005201 47907/anx_147907_cs.pdf.
3. Kilickap S, Sezer A, Özgüroğlu M et al. Cemiplimab monotherapy for first line advanced NSCLC patients with PD-L1 expression ≥ 50%: 5-y outcomes of EMPOWER-Lung 1. [online]. Available from: https: //www.jto.org/article/S1556-0864 (24) 00938-9/abstract.
4. Makharadze T, Gogishvili M, Melkadze T et al. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial. [online]. Available from: https: //www.jto.org/article/S1556-0864 (23) 00185-5/fulltext.
5. Baramidze A, Makharadze T, Gogishvili M et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: a subgroup analysis from the EMPOWER-Lung 3 part 2 trial. [online]. Available from: https: //www.sciencedirect.com/science/article/pii/S0169500224003556.
6. Antonia SJ, Villegas A, Daniel D et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379 (24): 2342–2350. doi: 10.1056/NEJMoa1809697.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2025 Issue 2
Most read in this issue
- Adherence to an exercise program and its impact on physical fitness, bone density and quality of life in women after breast cancer treatment
- Multimodal prehabilitation in oncogynecology – a case study
- Ivosidenib in the treatment of metastatic cholangiocarcinoma – a case report
- Napřimování čili rektifikace trajektorií v onkologii